In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Halozyme, with a price target of $79.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brendan Smith has given his Buy rating due to a combination of factors that highlight Halozyme’s strong financial performance and growth potential. The company reported impressive results for Q2, surpassing expectations in both revenue and earnings per share. This was largely driven by robust royalties from key products like Darzalex, Phesgo, and Vyvgart Hytrulo, which continue to perform well in the market.
Additionally, despite some uncertainties regarding CMS and IRA pricing timelines, Smith believes that Halozyme’s core business remains resilient. The company’s management has expressed confidence in their ongoing strategies, including potential new partnerships and product developments such as the ENHANZE technology. These factors collectively suggest a positive outlook for Halozyme, justifying the Buy rating.